Current Pain and Headache Reports

, Volume 14, Issue 2, pp 145–150 | Cite as

Intravenous Lidocaine and Mexiletine in the Management of Trigeminal Autonomic Cephalalgias

  • Michael J. MarmuraEmail author


Lidocaine and mexiletine are class 1B antiarrhythmic drugs that act on sodium channels. Lidocaine is also an important anesthetic and topical agent that is useful in the treatment of multiple pain disorders, and mexiletine is commonly used for neuropathic pain and myotonia. Both intravenous lidocaine and mexiletine are increasingly used to treat pain syndromes and appear to be particularly effective in neuropathic pain. This suggests a role for these agents in patients with headache disorders. This article describes the role of intravenous lidocaine and mexiletine in the management of headache and trigeminal autonomic cephalalgias based on the published literature to date and provides practical guidelines for their use.


Cluster SUNCT Lidocaine Chronic daily headache 



Dr. Michael J. Marmura has received funding from Merck for clinical research and has received compensation from Cephalon for speaking fees.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004, 24(Suppl 1):44–54.Google Scholar
  2. 2.
    Matharu MS, Cohen AS, Boes CJ, Goadsby PJ: Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003, 7:308–318.CrossRefPubMedGoogle Scholar
  3. 3.
    Malik K, Rizvi S, Vaillancourt PD: The SUNCT syndrome: successfully treated with lamotrigine. Pain Med 2002, 3:167–168.CrossRefPubMedGoogle Scholar
  4. 4.
    Montes E, Alberca R, Lozano P, et al.: Status-like SUNCT in two young women. Headache 2001, 41:826–829.CrossRefPubMedGoogle Scholar
  5. 5.
    Pareja JA, Caballero V, Sjaastad O: SUNCT syndrome. Status-like pattern. Headache 1996, 36:622–624.CrossRefPubMedGoogle Scholar
  6. 6.
    Carson IW, Lyons SM, Shanks RG: Anti-arrhythmic drugs. Br J Anaesth 1979, 51:659–670.CrossRefPubMedGoogle Scholar
  7. 7.
    Singh SN, Patrick J, Patrick J: Antiarrhythmic drugs. Curr Treat Options Cardiovasc Med 2004, 6:357–364.CrossRefPubMedGoogle Scholar
  8. 8.
    Mori K, Ito H, Toda Y, et al.: Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion. Epilepsia 2004, 45:1287–1290.CrossRefPubMedGoogle Scholar
  9. 9.
    Wyse DG, Morganroth J, Ledingham R, et al.: New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators. J Am Coll Cardiol 1994, 23:1130–1140.PubMedGoogle Scholar
  10. 10.
    Alexander JH, Granger CB, Sadowski Z, et al.: Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. Am Heart J 1999, 137:799–805.CrossRefPubMedGoogle Scholar
  11. 11.
    Pharand C, Kluger J, O’Rangers E, et al.: Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clin Pharmacol Ther 1995, 57:471–478.CrossRefPubMedGoogle Scholar
  12. 12.
    Sadowski ZP, Alexander JH, Skrabucha B, et al.: Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999, 137:792–798.CrossRefPubMedGoogle Scholar
  13. 13.
    Nichol G, McAlister F, Pham B, et al.: Meta-analysis of randomized controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002, 87:535–543.CrossRefPubMedGoogle Scholar
  14. 14.
    Fuster V, Rydén LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231–1266.CrossRefPubMedGoogle Scholar
  15. 15.
    Manolis AS, Deering TF, Cameron J, Estes NA 3rd: Mexiletine: pharmacology and therapeutic use. Clin Cardiol 1990, 13:349–359.CrossRefPubMedGoogle Scholar
  16. 16.
    Ochs HR, Carstens G, Greenblatt DJ: Reduction in lidocaine clearance. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 1980, 303:373–377.PubMedCrossRefGoogle Scholar
  17. 17.
    Collinsworth KA, Strong JM, Atkinson AJ Jr, et al.: Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clin Pharmacol Ther 1975, 18:59–64.PubMedGoogle Scholar
  18. 18.
    Gil-Gouveia R, Goadsby PJ: Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 2009, 29:496–508.CrossRefPubMedGoogle Scholar
  19. 19.
    Collinsworth KA, Kalman SM, Harrison DC: The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation 1974, 50:1217–1230.PubMedGoogle Scholar
  20. 20.
    Maeda Y, Funakoshi S, Nakamura M, et al.: Possible mechanism for pharmacokinetic interaction between lidocaine and mexiletine. Clin Pharmacol Ther 2002, 71:389–397.CrossRefPubMedGoogle Scholar
  21. 21.
    Tzeng JI, Cheng KI, Huang KL, et al.: The cutaneous analgesic effect of class I antiarrhythmic drugs. Anesth Analg 2007, 104:955–958.CrossRefPubMedGoogle Scholar
  22. 22.
    Woosley RL, Wang T, Stone W, et al.: Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J 1984, 107(5 Pt 2):1058–1065.CrossRefPubMedGoogle Scholar
  23. 23.
    Mao J, Chen LL: Systemic lidocaine for neuropathic pain relief. Pain 2000, 87:7–17.CrossRefPubMedGoogle Scholar
  24. 24.
    Hirota K, Okawa H, Appadu BL, et al.: Interaction of local anaesthetics with recombinant mu, kappa, and delta-opioid receptors expressed in Chinese hamster ovary cells. Br J Anaesth 2000, 85:740–746.CrossRefPubMedGoogle Scholar
  25. 25.
    Tejwani GA, Rattan AK, McDonald JS: Role of spinal opioid receptors in the antinociceptive interactions between intrathecal morphine and bupivacaine. Anesth Analg 1992, 74:726–734.CrossRefPubMedGoogle Scholar
  26. 26.
    Devor M, Wall PD, Catalan N: Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992, 48:261–268.CrossRefPubMedGoogle Scholar
  27. 27.
    Chabal C, Jacobson L, Mariano A, et al.: The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992, 76:513–517.PubMedCrossRefGoogle Scholar
  28. 28.
    Kamei J, Zushida K: Effect of mexiletine on thermal allodynia and hyperalgesia in diabetic mice. Jpn J Pharmacol 2000, 84:89–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Hitosugi H, Kashiwazaki T, Ohsawa M, Kamei J: Effects of mexiletine on algogenic mediator-induced nociceptive responses in mice. Methods Find Exp Clin Pharmacol 1999, 21:409–413.CrossRefPubMedGoogle Scholar
  30. 30.
    Muth-Selbach U, Hermanns H, Stegmann JU, et al.: Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic system. Eur J Pharmacol 2009, 613:68–73.CrossRefPubMedGoogle Scholar
  31. 31.
    Herroeder S, Pecher S, Schönherr ME, et al.: Systemic lidocaine shortens length of hospital stay after colorectal surgery: a double-blinded, randomized, placebo-controlled trial. Ann Surg 2007, 246:192–200. (Published erratum appears in Ann Surg 2009, 249:701.)Google Scholar
  32. 32.
    Bartlettt EE, Hutserani O: Xylocaine for the relief of postoperative pain. Anesth Analg 1961, 40:296–304.CrossRefGoogle Scholar
  33. 33.
    • Carroll I: Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy. Curr Pain Headache Rep 2007, 11:20–24. This review discusses lidocaine in the treatment of chronic neuropathic pain.CrossRefPubMedGoogle Scholar
  34. 34.
    Ackerman WE 3rd, Colclough GW, Juneja MM, Bellinger K: The management of oral mexiletine and intravenous lidocaine to treat chronic painful symmetrical distal diabetic neuropathy. J Ky Med Assoc 1991, 89:500–501.PubMedGoogle Scholar
  35. 35.
    Kastrup J, Petersen P, Dejgård A, et al.: Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy? Pain 1987, 28:69–75.CrossRefPubMedGoogle Scholar
  36. 36.
    Viola V, Newnham HH, Simpson RW: Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications 2006, 20:34–39.CrossRefPubMedGoogle Scholar
  37. 37.
    Wallace MS, Magnuson S, Ridgeway B: Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000, 25:459–467.PubMedGoogle Scholar
  38. 38.
    Tremont-Lukats IW, Challapalli V, McNicol ED, et al.: Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 2005, 101:1738–1749.CrossRefPubMedGoogle Scholar
  39. 39.
    Attal N, Gaude V, Brasseur L, et al.: Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2000, 54:564–574.PubMedGoogle Scholar
  40. 40.
    Schafranski MD, Malucelli T, Machado F, et al.: Intravenous lidocaine for fibromyalgia syndrome: an open trial. Clin Rheumatol 2009, 28:853.CrossRefPubMedGoogle Scholar
  41. 41.
    Kuhnert SM, Phillips WJ, Davis MD: Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 1999, 135:1447–1449.CrossRefPubMedGoogle Scholar
  42. 42.
    Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q: The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg 2002, 95:985–991.CrossRefPubMedGoogle Scholar
  43. 43.
    Sakurai M, Kanazawa I: Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999, 162:162–168.CrossRefPubMedGoogle Scholar
  44. 44.
    Cleland JC, Griggs RC: Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics 2008, 5:607–612.CrossRefPubMedGoogle Scholar
  45. 45.
    Carroll IR, Kaplan KM, Mackey SC: Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manage 2008, 35:321–326.CrossRefPubMedGoogle Scholar
  46. 46.
    Burke M: Intravenous lignocaine for migraine headache. Aust Fam Physician 1989,18:1559. (Published erratum appears in Aust Fam Physician 1990, 19:598.)Google Scholar
  47. 47.
    Reutens DC, Fatovich DM, Stewart-Wynne EG, Prentice DA: Is intravenous lidocaine clinically effective in acute migraine? Cephalalgia 1991, 11:245–247.CrossRefPubMedGoogle Scholar
  48. 48.
    Maciewicz R, Chung RY, Strassman A, et al.: Relief of vascular headache with intravenous lidocaine: clinical observations and a proposed mechanism. Clin J Pain 1988, 4:11–16.CrossRefGoogle Scholar
  49. 49.
    Jauslin P, Goadsby PJ, Lance JW: The hospital management of severe migrainous headache. Headache 1991, 31:658–660.CrossRefPubMedGoogle Scholar
  50. 50.
    Kaube H, Hoskin KL, Goadsby PJ: Lignocaine and headache: an electrophysiological study in the cat with supporting clinical observations in man. J Neurol 1994, 241:415–420.CrossRefPubMedGoogle Scholar
  51. 51.
    Williams DR, Stark RJ: Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003, 23:963–971.CrossRefPubMedGoogle Scholar
  52. 52.
    • Rosen N, Marmura M, Abbas M, Silberstein S: Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache 2009, 49:286–291. (Published erratum appears in Headache 2009, 49:803.). This is a large review of IV lidocaine in the treatment of chronic daily headache, including CH.CrossRefPubMedGoogle Scholar
  53. 53.
    Schere D, Silberstein SD: Intravenous lidocaine infusion for the treatment of post-acoustic neuroma resection headache: a case report. Headache 2009, 49:302–303.CrossRefPubMedGoogle Scholar
  54. 54.
    Scott RM: Mexiletine and vascular headaches. N Z Med J 1981, 93:92–93.PubMedGoogle Scholar
  55. 55.
    • Marmura MJ, Passero FC Jr, Young WB: Mexiletine for refractory chronic daily headache: a report of nine cases. Headache 2008, 48:1506–1510. This is a practical review of mexiletine in the treatment of refractory headache in a tertiary headache clinic. CrossRefPubMedGoogle Scholar
  56. 56.
    Cohen AS, Matharu MS, Goadsby PJ: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA): a prospective clinical study of SUNCT and SUNA. Brain 2006, 129:2746–2760.CrossRefPubMedGoogle Scholar
  57. 57.
    Pareja JA, Sjaastad O: SUNCT syndrome. A clinical review. Headache 1997, 37:195–202.CrossRefPubMedGoogle Scholar
  58. 58.
    Pareja JA, Joubert, J, Sjaastad, O: SUNCT syndrome. Atypical temporal patterns. Headache 1996, 36:108–110.CrossRefPubMedGoogle Scholar
  59. 59.
    Penart A, Firth M, Bowen JRC: Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) following presumed dorsolateral brainstem infarction. Cephalalgia 2001, 21:236.CrossRefPubMedGoogle Scholar
  60. 60.
    Vilisaar J, Constantinescu C: SUNCT in multiple sclerosis. Cephalalgia 2006, 26:891.CrossRefPubMedGoogle Scholar
  61. 61.
    Bussone G, Leone M, Volta GD, et al.: Short-lasting unilateral neuralgiform headache attacks with tearing and conjunctival injection: the first symptomatic case. Cephalalgia 1991, 11:123.CrossRefPubMedGoogle Scholar
  62. 62.
    Matharu MS, Cohen AS, Goadsby PJ: SUNCT syndrome responsive to intravenous lidocaine. Cephalalgia 2004, 24:985–992.CrossRefPubMedGoogle Scholar
  63. 63.
    • Cohen AS: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007, 27:824. This is the largest case series of lidocaine to treat SUNCT and SUNA; it also includes an excellent overview of their clinical features. CrossRefPubMedGoogle Scholar
  64. 64.
    Williams MH, Broadley SA: SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci 2008, 15:526–534.CrossRefPubMedGoogle Scholar
  65. 65.
    Arroyo AM, Durán XR, Beldarrain MG, et al.: Response to intravenous lidocaine in a patient with SUNCT syndrome. Cephalalgia 2009 Apr 30 (Epub ahead of print).Google Scholar
  66. 66.
    Ferrini R, Paice JA: How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 2004, 2:90–94.PubMedGoogle Scholar
  67. 67.
    • Cohen AS, Matharu MS, Goadsby PJ: Trigeminal autonomic cephalalgias: current and future treatments. Headache 2007, 47:969–980. This excellent review of the treatment of TACs provides evidence for each modality.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of NeurologyThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations